RecruitingNCT02961413
A Prospective Cohort Study on Drug-induced Liver Injury in China（DILI-P）
A Multi-center, Prospective, Non-interventional Cohort Study on Drug Induced Liver Injury in Mainland China
Sponsor
Drug Induced Liver Disease Study Group
Enrollment
10,000 participants
Start Date
Apr 1, 2016
Study Type
OBSERVATIONAL
Conditions
Summary
This is a multi-center, prospective, non-interventional cohort study . Its primary objectives are: 1. assess DILI patients' clinical characteristics, disease progression and influencing factors in clinical practice; 2. learn about suspected drug caused DILI,rechallenging, liver biochemical abnormalities mode, etc.
Eligibility
Inclusion Criteria3
- Diagnosis of DILI patients with various types and severity according to the 2015 version of the Chinese DILI treatment guidelines
- RUCAM ≥6, or RUCAM between 3-5 is required by the three experts determined that the drug-induced liver injury
- patient can provide informed consent form
Exclusion Criteria1
- non-drug-induced liver injury
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT02961413
Related Trials
Drug-induced Liver Injury: Itching Study
NCT064466091 location
Drug-Induced Liver Injury (DILI) Network Retrospective
NCT003606466 locations
Glucocorticoids for Acute Drug Induced Liver Injury With Hyperbilirubinemia
NCT069226691 location
A Prognostic Model for Drug-induced Liver Injury in China
NCT0506028913 locations
Screening of Susceptibility Genes for APAP Induced Drug Induced LIver Injury in ChiNese Population: a Case-control Study
NCT049643101 location